Synageva Biopharma raises $30 Million in equity financing
Printer Print Email Email
Waltham: Synageva BioPharma, a privately held biopharmaceutical company, has raised $30 million in a financing led by Baker Brothers Investments, a leading biotechnology investor. Other investors participating in the financing include Tullis Dickerson and Four Partners. As part of the transaction, Synageva announced that Robyn Samuels, Vice President with Tisch Family Interests, has joined its Board of Directors representing Four Partners. Subsequent closings of additional new and existing investors representing both large private equity and venture capital funds will occur over the next few weeks. These investments will be in addition to the $30 million already raised. Sanj K. Patel, Synageva's President and CEO said, "This investment is a strong affirmation of the technological advances we have made with the Synageva Expression Platform (SEP), the tremendous potential of our development programs, and the expertise of our science and management teams." This funding will be utilized to advance Synageva's products to later stages of development in order to maximize their value for partnership discussions. Specifically, the company will be advancing three of its most promising development programs through IND, including two monoclonal antibodies, and a novel protein therapeutic. Synageva is also pursuing partnerships for the development and commercialization of our later stage pipeline, in addition to collaborations with potential partner companies for producing other product candidates with favorable safety and efficacy profiles.

Digital Supply Chain Transformation – Winning the AI/ML Way